scispace - formally typeset
T

Tor Ole Klemsdal

Researcher at Oslo University Hospital

Publications -  56
Citations -  2784

Tor Ole Klemsdal is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 18, co-authored 51 publications receiving 2211 citations. Previous affiliations of Tor Ole Klemsdal include St Bartholomew's Hospital & University of Oslo.

Papers
More filters
Journal ArticleDOI

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, +113 more
- 21 Oct 2017 - 
TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.
Journal ArticleDOI

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, +200 more
- 08 Apr 2017 - 
TL;DR: Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes in this trial, with the limitation that withdrawn individuals were not followed up after discontinuation.
Journal ArticleDOI

Effect of diet or very long chain ω-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia:

TL;DR: In this paper, a randomized study targeted a comparison of the effect of 3-year diet counselling or ω-3 polyunsaturated fatty acid (PUFA) supplementation (2.4g/day) on the progression of atherosclero...